Could a drug combo make food allergy treatment safer?

NCT ID NCT03181009

Completed Disease control Sponsor: Andrew Long, PharmD Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tested whether the drug omalizumab (Xolair) can make oral immunotherapy safer for people with multiple food allergies. Sixty participants aged 2 to 25 received omalizumab before gradually increasing doses of their problem foods. The goal was to see if this approach allows lower maintenance doses and reduces allergic reactions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Omalizumab (Xolair) and food flour allergens
What this could lead to: If successful, this could point toward a safer way to treat multiple food allergies at once, possibly allowing lower daily doses of allergens.
What could go wrong: This is a small, early-phase study (60 people) focused on immune markers, not long-term outcomes. Results may not apply to everyone, and allergic reactions remain a risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOOD ALLERGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

food allergy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOOD ALLERGY

Contacts and locations

Locations

Sean N. Parker Center for Allergy and Asthma Research at Stanford

Mountain View, California, 94040, United States
UCLA

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.